MicroRNAs (miRNAs) regulate the expression of protein-coding genes and represent
potential biomarkers for childhood acute lymphoblastic leukemia (ALL). However …

Acute lymphoblastic leukemia (ALL) is a heterogeneous cancer commonly affecting children
due to dysregulation of miRNA expression. In the current study, authors investigated the …

Acute myeloid leukemia (AML) is a heterogeneous disease, and optimal treatment varies
according to cytogenetic risk factors and molecular markers. Several studies have …

Cytogenetically normal acute myeloid leukemia (CN-AML) is the largest and most
heterogeneous AML subgroup. It lacks sensitive and specific biomarkers. Emerging …

MicroRNAs (miRNAs) are small RNAs of 19 to 25 nucleotides that are negative regulators of
gene expression. To determine whether miRNAs are associated with cytogenetic …

Background Although the 5-year survival rates in pediatric acute myeloid leukemia (AML)
have improved over the last decades, there is a high relapse rate for Pediatric AML patients …

Background: The association between dysregulated microRNAs (miRNAs) and acute
myeloid leukemia (AML) is well known. However, our understanding of the regulatory role of …

Abstract Background Still 30–40% of pediatric acute myeloid leukemia (pedAML) patients
relapse. Delineation of the transcriptomic profile of leukemic subpopulations could aid in a …

PURPOSE Optimized strategies for risk classification are essential to tailor therapy for
patients with biologically distinctive disease. Risk classification in pediatric acute myeloid …

Pediatric acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous
disease accounting for about 20% of acute leukemia in children. Major advances have been …